

53. (Amended) The method according to claim 51 wherein the mucosal surface is a genital mucosal surface.

54. (Amended) The method according to 51 wherein the one or more antigens and TGF β is injected for systemic contact.

55. (Amended) The method according to claim 51 wherein the TGF β and the one or more antigens are administered at one site.

56. (Amended) The method according to claim 51 wherein said TGF β and said one or more antigens are each administered at a first site and a different site respectively.

57. (Amended) The method according to claim 50 wherein said TGF β and said one or more antigen are administered temporarily spaced apart.

58. (Amended) The method according to claim 57 wherein the one or more antigens are administered subsequent to an administration of the TGF β .

59. (Amended) The method according to claim 57 wherein the one or more antigens are administered first followed by administration of TGF β .

60. (Amended) The method according to claim 50 wherein the one or more antigens are chosen as a result of being particularly antigenic and prominent either on the sperm, or on the conceptus.

61. (Amended) The method according to claim 50 wherein the one or more antigens are present on cells taken from the prospective father that contain MHC antigens.

62. (Amended) The method according to claim 61 wherein the antigen is an MHC I antigen of the prospective father.

63. Cancelled.

64. (Amended) The method according to claim 50 wherein the one or more antigens are administered on sperm cells of the prospective father.

65. (Amended) The method according to claim 51 wherein the one or more antigens are administered on sperm cells of the prospective father.

66. (Amended) The method according to claim 50 wherein the one or more antigens are presented in purified or semi-purified form.

67. (Amended) The method according to claim 66 wherein the purified or semi-purified one or more antigens are presented on inert or adjuvant carriers.

68. (Amended) The method according to claim 51 wherein humans are being treated, and the exposure of TGF β is to a mucosal surface and the level of TGF β is greater than 50 ng/mL with a total dose of 150 ng/mL.

69. (Amended) The method according to claim 51 wherein the mucosal surface is exposed to a concentration of TGF β of between 100 and 400 ng/mL with a total dose of between 100 to 2000 ng.

70. (Amended) The method according to claim 50 wherein the TGF β is supplied in a slow release form.